Stay updated on Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Sign up to get notified when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.

Latest updates to the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now uses a general 'Locations' link instead of listing specific state locations (Arizona, California, Florida, Louisiana, Tennessee, Texas). It also adds 'Non-alcoholic fatty liver disease' and MedlinePlus Genetics as topics.SummaryDifference0.7%

- Check18 days agoChange DetectedThe page no longer lists the core condition 'Non-alcoholic fatty liver disease' and related topics such as MedlinePlus Genetics.SummaryDifference0.1%

- Check25 days agoChange DetectedAdded related topics Non-alcoholic fatty liver disease and MedlinePlus Genetics in the Related Topics section.SummaryDifference0.1%

- Check32 days agoChange DetectedThe page content no longer includes the term 'Non-alcoholic fatty liver disease' and the related topic 'MedlinePlus Genetics'.SummaryDifference0.1%

- Check39 days agoChange DetectedAdded 'Non-alcoholic fatty liver disease' as a study topic and related topic links (MedlinePlus Genetics); updated publication notes clarify that some content is provided voluntarily and auto-filled from PubMed, with a revision tag to v3.3.2. To avoid being alerted by small changes, set an alert condition below.SummaryDifference0.2%

- Check46 days agoChange DetectedA notice about government funding lapse and potential delays was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Selonsertib, Firsocostat, & Cilofexor in NASH Clinical Trial page.